Viking Therapeutics details obesity pipeline progress on Q2 2026 earnings call
The biotech used its quarterly call to lay out next steps for its obesity candidates.
TR
By Tom Reyes · Markets Editor
Jul 29 03:00 ETSource: Yahoo Finance
The wire
- 01Viking Therapeutics reported second-quarter 2026 results and used the earnings call to outline advances in its obesity development program.
- 02Viking is one of the few mid-cap challengers to Novo Nordisk and Eli Lilly in incretin-based obesity drugs, so its timelines shape competitive expectations.
- 03Specific trial timing, enrollment and financial figures come from the company's own call; independent data readouts remain the test.
From the source
Read at finance.yahoo.comViking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline ...
